1
|
Hein R, Koopman R, García M, Armour N, Dunn JR, Barbosa T, Martinez A. Review of Poultry Recombinant Vector Vaccines. Avian Dis 2021; 65:438-452. [PMID: 34699141 DOI: 10.1637/0005-2086-65.3.438] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 06/02/2021] [Indexed: 11/05/2022]
Abstract
The control of poultry diseases has relied heavily on the use of many live and inactivated vaccines. However, over the last 30 yr, recombinant DNA technology has been used to generate many novel poultry vaccines. Fowlpox virus and turkey herpesvirus are the two main vectors currently used to construct recombinant vaccines for poultry. With the use of these two vectors, more than 15 recombinant viral vector vaccines against Newcastle disease, infectious laryngotracheitis, infectious bursal disease, avian influenza, and Mycoplasma gallisepticum have been developed and are commercially available. This review focuses on current knowledge about the safety and efficacy of recombinant viral vectored vaccines and the mechanisms by which they facilitate the control of multiple diseases. Additionally, the development of new recombinant vaccines with novel vectors will be briefly discussed.
Collapse
Affiliation(s)
- Ruud Hein
- Consultant Poultry Diseases Molecular Vaccine Technology Georgetown DE 19947,
| | - Rik Koopman
- MSD Animal Health/Intervet International BV, Boxmeer, 5831 AN Netherlands
| | - Maricarmen García
- Poultry Diagnostic and Research Center, Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA 30602
| | - Natalie Armour
- Poultry Research and Diagnostic Laboratory, Department of Pathobiology and Population Medicine, College of Veterinary Medicine, Mississippi State University, Pearl, MS 39208
| | - John R Dunn
- United States Department of Agriculture, Agricultural Research Service, U.S. National Poultry Research Center, Southeast Poultry Research Laboratory, Athens, GA 30602
| | | | - Algis Martinez
- Cobb-Vantress Global Veterinary Services, Siloam Springs, AR 72761
| |
Collapse
|
2
|
Amoia CFAN, Nnadi PA, Ezema C, Couacy-Hymann E. Epidemiology of Newcastle disease in Africa with emphasis on Côte d'Ivoire: A review. Vet World 2021; 14:1727-1740. [PMID: 34475692 PMCID: PMC8404124 DOI: 10.14202/vetworld.2021.1727-1740] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 05/03/2021] [Indexed: 12/13/2022] Open
Abstract
For decades, Newcastle disease (ND) has long been recognized as a frontline viral disease that constrains poultry production throughout Africa. The need to update on the epidemiology of the disease is rife, due to the increasing importance of poultry farming. In addition, poultry farming serves as the top animal food source globally. However, in Africa, the greater population of poultry is reared under traditional and conventional husbandry methods. This hugely impedes the ability of management practices to be correctly embraced in limiting or excluding viral pathogens in the poultry production chain. We conducted this review to consolidate recently published studies in the field and provide an overview of the disease. We reviewed original studies conducted on ND, the current taxonomic classification of the virus, clinical signs of the disease, and laboratory diagnostic methods available for virus detection and typing. This review additionally examined the control methods currently used, including available or circulating vaccines, vaccinations, recent vaccine findings, and the main variants of the virus present in West Africa. More specifically, we present a review of the current status and available information on the disease in Côte d’Ivoire. The lack of up-to-date and relevant information on the current prevalence, socio-economic impact, and ethnoveterinary medicine used against ND is probably the main limitation for appropriate and effective decision-making for better control of this disease in Côte d’Ivoire.
Collapse
Affiliation(s)
- Charlie Franck Arthur N'Guessan Amoia
- Department of Animal Health and Production, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria.,LANADA/Central Laboratory for Animal Diseases, B.P 206 Bingerville, Côte d'Ivoire
| | - Pius Ajanwachukwu Nnadi
- Department of Animal Health and Production, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria
| | - Chuka Ezema
- Department of Animal Health and Production, Faculty of Veterinary Medicine, University of Nigeria, Nsukka, Enugu State, Nigeria
| | | |
Collapse
|
3
|
Dunn JR, Dimitrov KM, Miller PJ, Garcia M, Turner-Alston K, Brown A, Hartman A. Evaluation of Protective Efficacy When Combining Turkey Herpesvirus-Vector Vaccines. Avian Dis 2020; 63:75-83. [PMID: 31251522 DOI: 10.1637/11979-092818-reg.1] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2018] [Accepted: 12/14/2018] [Indexed: 11/05/2022]
Abstract
Turkey herpesvirus (HVT) is widely used as a vaccine against Marek's disease in chickens and recently as a vector for foreign genes from infectious bursal disease virus, Newcastle disease (ND) virus, infectious laryngotracheitis (ILT) virus, and avian influenza virus. Advantages of HVT-vector vaccines are that the vaccines do not contain live respiratory viruses or live infectious bursal disease virus able to replicate and cause disease or embryo mortality, they can be administered at hatch or in ovo, and they are relatively insensitive to interference from maternally derived antibodies. As producers have tried to combine HVT-vector vaccines to protect against additional diseases, reports have indicated that applying two vectored vaccines using the same HVT vector is reported to reduce the efficacy of one or both vaccines. To confirm this interference, we evaluated commercial vaccines from multiple companies, including products with inserts designed to protect against ND, infectious ILT, and infectious bursal disease (IBD). Using a standard dosage, we found that the ILT product was most severely affected by the addition of other vaccines, as demonstrated by a significant increase in clinical signs, significant decrease in weight gain, and increase in quantity of challenge virus observed from tracheal swabs collected from Days 3-5 postchallenge. The ND and IBD products were also affected by the addition of other vaccines, although in most cases differences compared to vaccination with the vector alone were not statistically significant. This study demonstrates the importance of following manufacturer guidelines and the need for validating alternative strategies to benefit from the high level of protection offered by vector vaccines.
Collapse
Affiliation(s)
- John R Dunn
- USDA, Agricultural Research Service, U.S. National Poultry Research Center, Avian Disease and Oncology Laboratory, East Lansing, MI 48823,
| | - Kiril M Dimitrov
- USDA, Agricultural Research Service, U.S. National Poultry Research Center, Southeast Poultry Research Laboratory, Athens, GA 30605
| | - Patti J Miller
- USDA, Agricultural Research Service, U.S. National Poultry Research Center, Southeast Poultry Research Laboratory, Athens, GA 30605
| | - Maricarmen Garcia
- Poultry Diagnostic and Research Center, College of Veterinary Medicine, University of Georgia, Athens, GA 30602
| | | | | | | |
Collapse
|
4
|
Palya V, Tatár-Kis T, Walkóné Kovács E, Kiss I, Homonnay Z, Gardin Y, Kertész K, Dán Á. Efficacy of a Recombinant Turkey Herpesvirus AI (H5) Vaccine in Preventing Transmission of Heterologous Highly Pathogenic H5N8 Clade 2.3.4.4b Challenge Virus in Commercial Broilers and Layer Pullets. J Immunol Res 2018; 2018:3143189. [PMID: 30584541 PMCID: PMC6280313 DOI: 10.1155/2018/3143189] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Revised: 08/24/2018] [Accepted: 09/04/2018] [Indexed: 12/31/2022] Open
Abstract
Outbreaks caused by the highly pathogenic avian influenza virus (HPAIV) H5N8 subtype clade 2.3.4.4 were first reported in 2014 in South Korea then spread very rapidly in Asia, to Europe, and for the first time, to North America. Efficacy of a recombinant HVT-AI (H5) vaccine (rHVT-H5) to provide clinical protection as well as to significantly reduce the shedding of an H5N8 challenge virus has already been demonstrated in SPF chickens. The aim of our studies was to test the efficacy of the same rHVT-H5 vaccine in controlling the transmission of a recent Hungarian HPAIV H5N8 challenge virus in commercial chickens. Broilers and layers were vaccinated at day old according to the manufacturer's recommendation and then challenged with a 2017 Hungarian HPAIV H5N8 (2.3.4.4b) isolate at 5 or 7 weeks of age, respectively. Evaluation of clinical protection, reduction of challenge virus shedding, and transmission to vaccinated contact birds was done on the basis of clinical signs/mortality, detection, and quantitation of challenge virus in oronasal and cloacal swabs (regularly between 1 and 14 days postchallenge). Measurement of seroconversion to AIV nucleoprotein was used as an indicator of infection and replication of challenge virus. Our results demonstrated that rHVT-H5 vaccination could prevent the development of clinical disease and suppress shedding very efficiently, resulting in the lack of challenge virus transmission to vaccinated contact chickens, regardless the type of birds. Single immunization with the tested rHVT-H5 vaccine proved to be effective to stop HPAIV H5N8 (2.3.4.4b) transmission within vaccinated poultry population under experimental conditions.
Collapse
Affiliation(s)
- Vilmos Palya
- Scientific Support and Investigation Unit, Ceva-Phylaxia, Ceva Animal Health, Budapest 1107, Hungary
| | - Tímea Tatár-Kis
- Scientific Support and Investigation Unit, Ceva-Phylaxia, Ceva Animal Health, Budapest 1107, Hungary
| | - Edit Walkóné Kovács
- Scientific Support and Investigation Unit, Ceva-Phylaxia, Ceva Animal Health, Budapest 1107, Hungary
| | - István Kiss
- Scientific Support and Investigation Unit, Ceva-Phylaxia, Ceva Animal Health, Budapest 1107, Hungary
| | - Zalán Homonnay
- Scientific Support and Investigation Unit, Ceva-Phylaxia, Ceva Animal Health, Budapest 1107, Hungary
| | | | | | - Ádám Dán
- Veterinary Diagnostic Directorate, National Food Chain Safety Office (NEBIH), Budapest 1149, Hungary
| |
Collapse
|
5
|
Recent advances in viral vectors in veterinary vaccinology. Curr Opin Virol 2018; 29:1-7. [PMID: 29477122 DOI: 10.1016/j.coviro.2018.02.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 02/04/2018] [Accepted: 02/07/2018] [Indexed: 02/08/2023]
Abstract
Viral vectored vaccines, particularly using vectors such as adenovirus, herpesvirus and poxviruses, are used widely in veterinary medicine, where this technology has been adopted much more quickly than in human medicine. There are now a large number of programmes to develop viral vector vaccine platforms for humans and very similar or identical vectors are being developed for veterinary medicine. The shared experiences of developing these new vaccine platforms across the two disciplines is accelerating progress, a striking example of the value of a 'One Health' approach. In particular, there is growing use of adenoviruses, either replicating or replication-incompetent, to create new vaccines for use in livestock or companion animals. Live replicating avian herpesvirus vectors are increasingly used as vaccines against poultry diseases.
Collapse
|
6
|
Mayers J, Mansfield KL, Brown IH. The role of vaccination in risk mitigation and control of Newcastle disease in poultry. Vaccine 2017; 35:5974-5980. [PMID: 28951084 DOI: 10.1016/j.vaccine.2017.09.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2017] [Revised: 08/18/2017] [Accepted: 09/01/2017] [Indexed: 11/27/2022]
Abstract
Newcastle disease is regarded as one of the most important avian diseases throughout the world and continues to be a threat and economic burden to the poultry industry. With no effective treatment, poultry producers rely primarily on stringent biosecurity and vaccination regimens to control the spread of this devastating disease. This concise review provides an historical perspective of Newcastle disease vaccination and how fundamental research has paved the way for the development of instrumental techniques which are still in use today. Although vaccination programmes have reduced the impact of clinical disease, they have historically been ineffective in controlling the spread of virulent viruses and therefore do not always offer an adequate solution to the world's food security problems. However, the continued development of novel vaccine technology and improved biosecurity measures through education may offer a solution to help reduce the global threat of Newcastle disease on the poultry industry.
Collapse
Affiliation(s)
- Jo Mayers
- Virology Department, Animal and Plant Health Agency (APHA), Woodham Lane, New Haw, Surrey KT15 3NB, United Kingdom.
| | - Karen L Mansfield
- Virology Department, Animal and Plant Health Agency (APHA), Woodham Lane, New Haw, Surrey KT15 3NB, United Kingdom; Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom
| | - Ian H Brown
- Virology Department, Animal and Plant Health Agency (APHA), Woodham Lane, New Haw, Surrey KT15 3NB, United Kingdom
| |
Collapse
|
7
|
Dimitrov KM, Afonso CL, Yu Q, Miller PJ. Newcastle disease vaccines-A solved problem or a continuous challenge? Vet Microbiol 2016; 206:126-136. [PMID: 28024856 PMCID: PMC7131810 DOI: 10.1016/j.vetmic.2016.12.019] [Citation(s) in RCA: 192] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Revised: 12/10/2016] [Accepted: 12/15/2016] [Indexed: 01/11/2023]
Abstract
Newcastle disease (ND) has been defined by the World Organisation for Animal Health as infection of poultry with virulent strains of Newcastle disease virus (NDV). Lesions affecting the neurological, gastrointestinal, respiratory, and reproductive systems are most often observed. The control of ND must include strict biosecurity that prevents virulent NDV from contacting poultry, and also proper administration of efficacious vaccines. When administered correctly to healthy birds, ND vaccines formulated with NDV of low virulence or viral-vectored vaccines that express the NDV fusion protein are able to prevent clinical disease and mortality in chickens upon infection with virulent NDV. Live and inactivated vaccines have been widely used since the 1950's. Recombinant and antigenically matched vaccines have been adopted recently in some countries, and many other vaccine approaches have been only evaluated experimentally. Despite decades of research and development towards formulation of an optimal ND vaccine, improvements are still needed. Impediments to prevent outbreaks include uneven vaccine application when using mass administration techniques in larger commercial settings, the difficulties associated with vaccinating free-roaming, multi-age birds of village flocks, and difficulties maintaining the cold chain to preserve the thermo-labile antigens in the vaccines. Incomplete or improper immunization often results in the disease and death of poultry after infection with virulent NDV. Another cause of decreased vaccine efficacy is the existence of antibodies (including maternal) in birds, which can neutralize the vaccine and thereby reduce the effectiveness of ND vaccines. In this review, a historical perspective, summary of the current situation for ND and NDV strains, and a review of traditional and experimental ND vaccines are presented.
Collapse
Affiliation(s)
- Kiril M Dimitrov
- Exotic and Emerging Avian Viral Disease Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, USDA/ARS, Athens, GA, 30605, USA
| | - Claudio L Afonso
- Exotic and Emerging Avian Viral Disease Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, USDA/ARS, Athens, GA, 30605, USA
| | - Qingzhong Yu
- Endemic Poultry Viral Diseases Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, USDA/ARS, Athens, GA, 30605, USA
| | - Patti J Miller
- Exotic and Emerging Avian Viral Disease Research Unit, Southeast Poultry Research Laboratory, United States National Poultry Research Center, USDA/ARS, Athens, GA, 30605, USA.
| |
Collapse
|